Overview

A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara (Both Combined With the CDK4/6 Inhibitor Palbociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Advanced Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2031-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara (oral tablet), both given together with palbociclib, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Rovi Pharmaceuticals Laboratories

Treatments:

Letrozole
palbociclib